Emulsification by TPGS or Quillaja Extract Increased Absorption and Affected Metabolism of Berberine in Humans
Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally i...
Saved in:
Published in | Current developments in nutrition Vol. 5; no. Supplement_2; p. 381 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Inc
01.06.2021
Oxford University Press |
Subjects | |
Online Access | Get full text |
ISSN | 2475-2991 2475-2991 |
DOI | 10.1093/cdn/nzab037_091 |
Cover
Abstract | Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers.
Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance.
The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification.
Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers.
Florida High Tech Corridor Council and Designs for Health. |
---|---|
AbstractList | Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers.
Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance.
The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification.
Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers.
Florida High Tech Corridor Council and Designs for Health. Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers. Methods Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance. Results The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification. Conclusions Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers. Funding Sources Florida High Tech Corridor Council and Designs for Health. Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The objectives of this study were to determine whether emulsification by TPGS or Quillaja extract affect the absorption and metabolism of orally ingested berberine in human volunteers. Methods Twelve healthy subjects (7 male and 5 females, 21–50-year-old) participated this study. Each subject received 800 mg berberine in a powder form or emulsified with TPGS or Quillaja extract using a randomized crossover design with one-week washout period. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 6, 8, and 12 hours after dose. Plasma was hydrolyzed with glucuronidase and sulfatase before total content of berberine and its metabolites were analyzed on LC/MS/MS. Free forms of metabolites were determined in plasma without hydrolysis. Pharmacokinetic parameters were calculated using a non-compartment model before they were compared by analysis of covariance. Results The area under the curve (AUC) and peak plasma concentration (Cmax) of berberine was 6.6 μM.hr and 0.9 μM in participants received berberine powder. They were increased to 18.3 μM.hr and 4.5 μM by TPGS emulsification and 28 μM.hr and 5.1 μM by Quillaja extract emulsification, respectively. Berberrubine and demethylberberine were major metabolites of berberine. The AUC of free Berberrubine and demethylberberine was increased by 1.9 fold and 1.6 fold by TPGS and 5.9 folds and 2.7 folds by Quillaja extract, respectively, compared to berberine powder. Participants received berberine powder had AUC of 254 μM.hr and Cmax of 33 μM for total berberrubine. TPGS emulsification increased these values to 425 μM.hr and 54 μM, while Quillaja extract increased them to 341 μM.hr and 44 μM, respectively. Significant increases of AUC and Cmax were also observed for total demethylberberine by TPGS or Quillaja extract emulsification. Conclusions Emulsification of berberine with TPGS or Quillaja extract significantly increased the absorption of berberine and its metabolites in human compared to berberine supplement without emulsifiers. Funding Sources Florida High Tech Corridor Council and Designs for Health. |
Author | Wang, Gary Gu, Liwei Yagiz, Yavuz |
Author_xml | – sequence: 1 givenname: Yavuz surname: Yagiz fullname: Yagiz, Yavuz organization: University of Florida – sequence: 2 givenname: Gary surname: Wang fullname: Wang, Gary organization: University of Florida – sequence: 3 givenname: Liwei surname: Gu fullname: Gu, Liwei organization: University of Florida |
BookMark | eNqNkstvVCEUxompiXXs2i2JO5NxYOA-2JjUZvpIatRY14QLB2XkwhXurY5_fWlvE2sXoyte5_flfN_hOToIMQBCLyl5Q4lgK23CKvxWHWGNJII-QYdr3lTLtRD04MH-GTrKeUsIoUKImohDFDb95LOzTqvRxYC7Hb76ePYZx4Q_Tc57tVV482tMSo_4IugEKoPBx12OabgDVChHa0GP5f49jKqL3uUeR4vfQeoguQDYBXw-9SrkF-ipVT7D0f26QF9ON1cn58vLD2cXJ8eXS804o8tOC61aa2ndMG5r2jZroMaaFoggNVWct7xdQ8UJg6bqNBMcgLeEaqOUAcEWiMy6UxjU7qfyXg7J9SrtJCXyNjJZIpMPIivI2xkZpq4HoyEU13-wqJz8-yW4b_JrvJYtbWldOlmgV_cCKf6YII9yG6cUik3JaC0qIqpiboGquUqnmHMCK7Ub77Ivos7vaW_1iPu3odczEafhP4rFXAxlKtcOkszaQdBgXCqzlSa6PWzziNXehfKj_HfY7SVvAHo-3eU |
CitedBy_id | crossref_primary_10_3390_ijms25136994 |
ContentType | Journal Article |
Copyright | 2021 American Society for Nutrition. Copyright © The Author(s) on behalf of the American Society for Nutrition 2021. 2021 Copyright © The Author(s) on behalf of the American Society for Nutrition 2021. |
Copyright_xml | – notice: 2021 American Society for Nutrition. – notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2021. 2021 – notice: Copyright © The Author(s) on behalf of the American Society for Nutrition 2021. |
DBID | 6I. AAFTH AAYXX CITATION 3V. 7RV 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PHGZM PHGZT PIMPY PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 5PM ADTOC UNPAY |
DOI | 10.1093/cdn/nzab037_091 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
DatabaseTitleList | Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 2475-2991 |
EndPage | 381 |
ExternalDocumentID | 10.1093/cdn/nzab037_091 PMC8181640 10_1093_cdn_nzab037_091 S2475299123108997 |
GroupedDBID | .1- .FO 0R~ 7RV 7X7 8FI 8FJ AAFWJ AAHBH AALRI AAPXW AAVAP AAXUO AAYWO ABPTD ABUWG ABXVV ACGFS ACVFH ADBBV ADCNI ADVLN AEUPX AFJKZ AFKRA AFPKN AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMNDL AMRAJ AOIJS APXCP BAYMD BCNDV BENPR CCPQU EBS EJD EMOBN FDB FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR INH ITC KSI M~E NAPCQ O9- OK1 PHGZM PHGZT PIMPY PPXIY PUEGO RPM UKHRP Z5R 6I. AAFTH ABDBF AFCTW AFULF BTTYL OJZSN ROX TOX 0SF AAYXX CITATION 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 5PM ADTOC UNPAY |
ID | FETCH-LOGICAL-c3431-bc9ca8ff16734f61872e1dfd8e09061a448482e5403e75bc394ee4801cdaade93 |
IEDL.DBID | BENPR |
ISSN | 2475-2991 |
IngestDate | Mon Sep 15 10:18:45 EDT 2025 Tue Sep 30 15:59:07 EDT 2025 Fri Sep 19 20:55:38 EDT 2025 Wed Oct 01 01:49:08 EDT 2025 Thu Apr 24 23:04:50 EDT 2025 Wed Aug 28 03:17:29 EDT 2024 Fri Feb 23 02:36:48 EST 2024 Tue Aug 26 16:33:02 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_2 |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) cc-by |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3431-bc9ca8ff16734f61872e1dfd8e09061a448482e5403e75bc394ee4801cdaade93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
OpenAccessLink | https://www.proquest.com/docview/3169509534?pq-origsite=%requestingapplication%&accountid=15518 |
PQID | 3169509534 |
PQPubID | 7121353 |
PageCount | 1 |
ParticipantIDs | unpaywall_primary_10_1093_cdn_nzab037_091 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8181640 proquest_journals_3169509534 crossref_citationtrail_10_1093_cdn_nzab037_091 crossref_primary_10_1093_cdn_nzab037_091 oup_primary_10_1093_cdn_nzab037_091 elsevier_sciencedirect_doi_10_1093_cdn_nzab037_091 elsevier_clinicalkey_doi_10_1093_cdn_nzab037_091 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20210601 |
PublicationDateYYYYMMDD | 2021-06-01 |
PublicationDate_xml | – month: 06 year: 2021 text: 20210601 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford |
PublicationTitle | Current developments in nutrition |
PublicationYear | 2021 |
Publisher | Elsevier Inc Oxford University Press |
Publisher_xml | – name: Elsevier Inc – name: Oxford University Press |
SSID | ssj0001999609 |
Score | 2.1498156 |
Snippet | Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in human. The... Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in... Objectives Berberine is a botanical alkaloid used widely for the prevention of several diseases. However, the absorption rate of berberine is less than 1% in... |
SourceID | unpaywall pubmedcentral proquest crossref oup elsevier |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 381 |
SubjectTerms | Dietary Bioactive Components Metabolism Metabolites |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wAvfA1EYSBLIAQP6ZI48cdjQR0V0qYhVmk8WbbjaIXUnZpE0P31nPNRrUNl8JjEFzm-y_l39t3PCL1RTJNYcRpE1mQQoLAwUMzwwNA0zyNluVa-OPn4hE5nyefz9LwjSfK1MFv794IcmswduiulQ8Jk6KvU92gKYfIA7c1OTsff_NFxCUsDcKpRT9zzp9SuOWerpM0jy5t5kXdrd6nWP1VRXJt0jh6gad_dNtfkx6iu9Mhc3WBy_IfveYjud8ATj1tLeYTuWPcY7Y8dBN2LNX6Lm1TQZo19H7nJoi5Kn0TU6A3rNT47_fQVL1f4S-2PKfqu8ORX5QusMDgYn9duMzzW5XLVeCCsHFw2mSJw_9hWYGnFvFzgZY4_gB6bkkM8d7jZQiifoNnR5OzjNOgOZggMAcARaCOM4qBLykiS04iz2EZZnnEbCsAHCkK-hMcWwCCxLNWGiMRaz1NjMqUyK8hTNHBLZ58hzFOhGFFC5FQkOqOcWhEaBkEWsTqP9RCNetVJ07GW-8MzCtnunhMJIyqvjegQvdsIXLaEHbubhr0tyL4OFTynBJ3tFok3Ih1EaaHH34Veg6Hd3puD3hBl50dKSSIqUk8JmAwR2zLOzes8P_j2Eze_aHjCAYtBMBwO0fuNGd_Wief_0fYFuhf7BJ9mSeoADapVbV8CQqv0q-7v_A16mT3l priority: 102 providerName: Unpaywall |
Title | Emulsification by TPGS or Quillaja Extract Increased Absorption and Affected Metabolism of Berberine in Humans |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2475299123108997 https://dx.doi.org/10.1093/cdn/nzab037_091 https://www.proquest.com/docview/3169509534 https://pubmed.ncbi.nlm.nih.gov/PMC8181640 https://doi.org/10.1093/cdn/nzab037_091 |
UnpaywallVersion | publishedVersion |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2475-2991 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: DOA dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2475-2991 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: M~E dateStart: 20170101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2475-2991 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: RPM dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health Medical collection customDbUrl: eissn: 2475-2991 dateEnd: 20221231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: 7X7 dateStart: 20170101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2475-2991 dateEnd: 20221231 omitProxy: true ssIdentifier: ssj0001999609 issn: 2475-2991 databaseCode: BENPR dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELe27gFeEGwgCqOyBELwEJrESRw_INShbhPSqgKrVJ4if0UrSp3StILur9_ZTboVqdujk1xk5S53vzvfB0LvOBUk5GniBVoqcFCo73EqU08mcZ4HXKeC2-Lki0FyPoq-jePxHho0tTA2rbLRiU5Rq1LaGHmXBAmLbXO06Mvsj2enRtnT1WaEBq9HK6jPrsXYPjqwKjlqoYOT_mD44zbqYvG9z5oeP4x0pTJdc82FT2jms2CXedqqfrMg9P8UykdLM-Orv7wo7tin06foSQ0scW8tCc_QnjaH6KhnwKmervB77FI9XQz9CJn-dFlUNknI8QWLFb4cnv3E5Rx_X9oxRL857v9b2AIqDArE5q1rhXuiKudOw2BuYOkyQeD6hV6AJBWTaorLHJ8An1xJIZ4Y7I4IqudodNq__Hru1YMXPEkAUHhCMslT4FVCSZQnQUpDHahcpdpnYP85uHRRGmoAe0TTWEjCIq1tHxqpOFeakReoZUqjXyKcxoxTwhnLExYJlaSJZr6k4EQRLfJQtNGn5ntnsu5KbodjFNn6dJxkwKDsDoPa6MOGYLZuyLH7Ub9hYNbUmYJmzMBY7CYJNyQ1BFlDi_uJ3oJ0PLyb40Z6slpPVNmtVLcR3ZKozets_-_tO2Zy5fqAA9YCZ9dvo48b2XtoE6_u38Rr9Di0OTsuynSMWov5Ur8B0LUQHbRPx7RT_08dF7qA1Wgw7P26AT4mNUA |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5V6aFcEFAQgRZW4iE4mNhev_ZQoRRSUtpEBVKpN3dfFqmcdYgTlfDj-G3Mbuy0QUp76tGPsVae2XntzDcIvWYxJz5LIsdTQkKAErsOi0XiiCjMMo-phDPTnNzrR93T4OtZeLaB_ta9MKasstaJVlHLQpgceYt4EQ0NOFrwcfzLMVOjzOlqPUKDVaMV5J6FGKsaO47U_BJCuHLv8DPw-43vH3QGn7pONWXAEQSsp8MFFSyBhUUxCbLIS2JfeTKTiXIpGDsG8UuQ-Ao8G6LikAtCA6UM6IqQjEllwJjABGyC2-EHDbS53-mffL_K8ph4wqU1phAlLSF1S_9h3CVx6lJvnTlc6bYzTu__JZtbMz1m80uW59fs4cEDdL9yZHF7IXkP0YbSj9B2W0MQP5rjt9iWltqc_TbSndEsL01RkpUDzOd4cPLlBy4m-NvMjD26YLjze2oatjAoLFMnryRu87KYWI2GmYZLW3kC93tqCpKbD8sRLjK8D3JhWxjxUGN7JFE-Rqd3woInqKELrZ4inISUxYRRmkU04DJKIkVdEUPQRhTPfN5EH-r_nYoKBd0M48jTxWk8SYFB6TUGNdG7JcF4AQCy_lW3ZmBa97WCJk7BOK0n8ZcklcuzcGVuJnoF0nH7anZq6UkrvVSmV7uoieIViVp-zuCNrz7Rw58Wdxx8Owiu3SZ6v5S92xbx7OZFvERb3UHvOD0-7B89R_d8Uy9kM1w7qDGdzNQuOHxT_qLaVRid3_VG_gdHwW5T |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdQ9wAvfA1EYSBLIAQP6ZI48cdjQR0V0qYhVmk8WbbjaIXUnZpE0P31nPNRrUNl8JjEFzm-y_l39t3PCL1RTJNYcRpE1mQQoLAwUMzwwNA0zyNluVa-OPn4hE5nyefz9LwjSfK1MFv794IcmswduiulQ8Jk6KvU92gKYfIA7c1OTsff_NFxCUsDcKpRT9zzp9SuOWerpM0jy5t5kXdrd6nWP1VRXJt0jh6gad_dNtfkx6iu9Mhc3WBy_IfveYjud8ATj1tLeYTuWPcY7Y8dBN2LNX6Lm1TQZo19H7nJoi5Kn0TU6A3rNT47_fQVL1f4S-2PKfqu8ORX5QusMDgYn9duMzzW5XLVeCCsHFw2mSJw_9hWYGnFvFzgZY4_gB6bkkM8d7jZQiifoNnR5OzjNOgOZggMAcARaCOM4qBLykiS04iz2EZZnnEbCsAHCkK-hMcWwCCxLNWGiMRaz1NjMqUyK8hTNHBLZ58hzFOhGFFC5FQkOqOcWhEaBkEWsTqP9RCNetVJ07GW-8MzCtnunhMJIyqvjegQvdsIXLaEHbubhr0tyL4OFTynBJ3tFok3Ih1EaaHH34Veg6Hd3puD3hBl50dKSSIqUk8JmAwR2zLOzes8P_j2Eze_aHjCAYtBMBwO0fuNGd_Wief_0fYFuhf7BJ9mSeoADapVbV8CQqv0q-7v_A16mT3l |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emulsification+by+TPGS+or+Quillaja+Extract+Increased+Absorption+and+Affected+Metabolism+of+Berberine+in+Humans&rft.jtitle=Current+developments+in+nutrition&rft.au=Yagiz%2C+Yavuz&rft.au=Wang%2C+Gary&rft.au=Gu%2C+Liwei&rft.date=2021-06-01&rft.pub=Oxford+University+Press&rft.eissn=2475-2991&rft.volume=5&rft.spage=381&rft_id=info:doi/10.1093%2Fcdn%2Fnzab037_091 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2475-2991&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2475-2991&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2475-2991&client=summon |